ITO EN Oi Ocha Green Teas Coming Soon to Walmart
30.7.2019 15:15:00 EEST | Business Wire | Press release
ITO EN (North America) INC. the global leaders of green tea and innovators of healthy beverages today announced that their Oi Ocha ready-to-drink green tea brand, will soon be available in Walmart stores nationwide. Slated for placement in October 2019 with two unsweetened flavors- ITO EN’s premium Oi Ocha green tea, Japan’s top selling brand and Jasmine Green Tea, a popular green tea infused with jasmine flowers. The award-winning teas are celebrated for their naturally smooth taste and clean finish, brewed with ITO EN’s proprietary brewing method using whole tea leaves without artificial additives, flavors or colors, and powders or concentrates. The authentic and refreshing teas are Non-GMO certified with natural catechin tea antioxidants, natural Vitamin C (Ascorbic Acid) and zero calories. Each packaged in a convenient on the go 16.9 fl. oz recyclable PET bottle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190730005425/en/
ITO EN Oi Ocha and Jasmine Green Tea. (Photo: Business Wire)
“With a growing number of consumers looking for authentic and healthy beverages, we could not be more excited to expand Ito En’s tea products into Walmart stores nationwide,” says Jim Hoagland, COO at ITO EN (North America) INC. “With Walmart responding to the growing consumer interest for high-quality, authentic and better-for-you products, we are confident that our traditional unsweetened green teas are a great fit for Walmart and their customers.”
The Oi Ocha brand has been growing exponentially in the U.S. market as consumer demand for authentic and healthier beverages continues to grow across the specialty, mainstream markets, and food service channels. The partnership with Walmart not only broadens ITO EN’s brand awareness and distribution but will also give accessibility to a better-for-you beverage to the everyday consumer. With green tea gaining popularity for its health benefits while consumers seek sugar free beverages, unsweetened Oi Ocha teas are ideal to integrate into daily life.
ITO EN is specifically known for its commitment to tea expertise and sustainable practices that are reflected across all of its award-winning brands. With over 50 years of tea expertise, the company is dedicated to authenticity, preserving its culture while creating global innovation for the tea and beverage industry. ITO EN is proud to have ranked #18 in FORTUNE's top 50 Companies that have made an important social or environmental impact through its profit-making strategy and operations. The company was also awarded a sustainability award for its used tea leaf recycling program, creating innovative products from a eco-friendly synthetic resin made from used tea leaves. For more information on ITO EN and its products, please visit www.itoen.com.
About ITO EN:
ITO EN (North America) INC., a subsidiary of ITO EN (Japan) LTD., is an innovative beverage industry leader dedicated to creating authentic products that embody the company’s five principles of Natural, Healthy, Safe, Well-designed and Delicious. With over 50 years of tea expertise in Japan, ITO EN is dedicated to authenticity, preserving its culture while creating global innovation, making it known as Japan’s #1 green tea purveyor with award-winning brands, including TEAS’ TEA Organic®, Oi Ocha®, ITO EN Shots® and matcha LOVE®. ITO EN’s strong commitment to social and environmental impact manifests in its partnerships with regional farmers and governments to stimulate local economies, development of sustainable procurement practices and nurture a new generation of tea farming. To learn more about ITO EN, visit www.itoen.com. ‘Like’ us on Facebook or follow us on Twitter and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190730005425/en/
Contact information
Rona Tison
ITO EN (North America) INC.
rtison@itoen.com
T. 707-327-6413
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom